Patents by Inventor David H. Raulet

David H. Raulet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Modulating Activity of a Cyclic Dinucleotide (CDN) with a CDN Transporter-Modulating Agent
    Publication number: 20210275547
    Abstract: Methods of modulating the activity of a cyclic dinucleotide (CDN) in a cell via membrane transporter are provided. Aspects of the methods may include contacting a cell with a CDN transporter-modulating agent to modulate transport of a CDN into the cell. In some cases, the CDN transporter-modulating agent modulates SLC19A1-mediated transport of the CDN into the cell. Also provided are compositions and kits for use in practicing the subject methods. The methods and compositions find use in a variety of applications, including therapeutic applications, such as methods of treating cancer or an inflammatory disease.
    Type: Application
    Filed: May 16, 2019
    Publication date: September 9, 2021
    Applicant: The Regents of the University of California
    Inventors: David H. RAULET, Rutger D. LUTEIJN, Jacob E. CORN
  • Use of NKG2D Inhibitors for Treating Cardiovascular and Metabolic Diseases, Such as Type 2 Diabetes
    Publication number: 20150376281
    Abstract: The present invention provides methods, compositions and kits for treating and detecting type 2 diabetes and/or conditions that may be regulated or normalised via inhibition of NKG2D, such as cardiovascular diseases.
    Type: Application
    Filed: September 10, 2015
    Publication date: December 31, 2015
    Inventors: Na Xiong, Mingcan Xia, David H. Raulet, Jacob Sten Petersen, Thora Brynja Bodvarsdottir
  • USE OF NKG2D INHIBITORS FOR TREATING CARDIOVASCULAR AND METABOLIC DISEASES, SUCH AS TYPE 2 DIABETES
    Publication number: 20120148581
    Abstract: The present invention provides methods, compositions and kits for treating and detecting type 2 diabetes and/or conditions that may be regulated or normalised via inhibition of NKG2D, such as cardiovascular diseases.
    Type: Application
    Filed: August 16, 2010
    Publication date: June 14, 2012
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE PENN STATE RESEARCH FOUNDATION
    Inventors: Na Xiong, Mingcan Xia, David H. Raulet, Jacob Sten Petersen, Thora Brynja Bodvarsdottir
  • Tumor Therapy
    Patent number: 6821522
    Abstract: Neoplasia is treated by administering to a mammalian host a composition comprising ligands for the NKG2D receptor. In addition, other NKG2D ligands, proteins specific for the neoplastic cells and cytokines may be included to enhance the immune response. The composition may be cells comprising expression constructs for the ligands, liposomes or combinations of protein molecules.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: November 23, 2004
    Assignee: The Regents of the University of California
    Inventors: David H. Raulet, Andreas Diefenbach
  • Tumor Therapy
    Publication number: 20020187151
    Abstract: Neoplasia is treated by administering to a mammalian host a composition comprising ligands for the NKG2D receptor. In addition, other NKG2D ligands, proteins specific for the neoplastic cells and cytokines may be included to enhance the immune response. The composition may be cells comprising expression constructs for the ligands, liposomes or combinations of protein molecules.
    Type: Application
    Filed: May 31, 2001
    Publication date: December 12, 2002
    Inventors: David H. Raulet, Andreas Diefenbach
  • Tumor therapy
    Patent number: RE39789
    Abstract: Neoplasia is treated by administering to a mammalian host a composition comprising ligands for the NKG2D receptor. In addition, other NKG2D ligands, proteins specific for the neoplastic cells and cytokines may be included to enhance the immune response. The composition may be cells comprising expression constructs for the ligands, liposomes or combinations of protein molecules.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: August 21, 2007
    Inventors: David H. Raulet, Andreas Diefenbach